BACKGROUND: It is common practice for surgeons to obtain a craniomaxillofacial computed tomography (CT) scan to evaluate fracture reduction and implant positioning following the surgical reconstruction of facial fractures. CT scans contribute to the potential stochastic health risk from cumulative radiation exposure. This study was aimed at testing the hypothesis that an ultralow dose CT protocol is effective for postoperative diagnostic evaluation of craniomaxillofacial fractures.
METHODS:
This observational study was conducted at a level 1 trauma center. We included patients for whom CT was indicated for postoperative evaluation of their reconstructed craniomaxillofacial fractures. Postoperative craniomaxillofacial CT was performed utilizing an ultralow-dose protocol (0.1 mSv), rather than the standard protocol (3.6 mSv). A craniomaxillofacial surgeon and a radiologist independently interpreted the images to determine whether the image quality was adequate for assessing fracture reduction and implant position. It was decided a priori that any inadequate ultralowdose CT would require repeat scanning utilizing the standard protocol. The primary endpoint was the need for repeat CT, as determined by the surgeon or radiologist.
RESULTS:
Twenty patients met inclusion criteria. Mean radiation dose (total dose-length product) from the ultralowdose protocol was 71 versus 532 mGycm for the preoperative CTs which were performed using the regular protocol (P < 0.001). All 20 patients' ultralow-dose postoperative CTs were determined to be satisfactory. No patient required repeat CT secondary to poor image quality of the ultralow-dose scans.
CONCLUSIONS:
Our ultralow-dose CT protocol which delivers 7.5-fold less radiation than the standard protocol seems adequate for routine postoperative evaluation of reconstructed facial fractures. Larger prospective studies may be warranted.
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METHODS:
The protein expressions of PARP1 and smad3 were evaluated with western blotting in keloids and controls. The effect of rucaparib was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and migration assay. We further analyze the effect of rucaparib on patient-derived keloid xenograft murine model.
RESULTS:
The protein expressions of PARP1 and smad3 were significantly higher in keloid tissue. Rucaparib (20 μM) significantly suppressed the proliferation of keloid fibroblasts. Moreover, the combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts. Migration assay showed rucaparib (10 μM) significantly suppressed the migration of keloid fibroblasts. Fibrosis markers in keloid fibroblasts significantly decreased after rucaparib treatment (20 μM). In patient-derived keloid xenograft model, rucaparib significantly reduced the size of keloid tissue.
CONCLUSION:
The study data suggest that PARP1 might be a novel therapeutic target for keloid disease. Rucaparib might be a promising therapeutic drug for the treatment of keloid disease.
